Plasma β-Amyloid in Mild Behavioural Impairment - Neuropsychiatric Symptoms on the Alzheimer's Continuum.

Abstract

INTRODUCTION:

Simple markers are required to recognize older adults at higher risk for neurodegenerative disease. Mild behavioural impairment (MBI) and plasma β-amyloid (Aβ) have been independently implicated in the development of incident cognitive decline and dementia. Here we studied the associations between MBI and plasma Aβ42/Aβ40.

METHODS:

Participants with normal cognition (n = 86) or mild cognitive impairment (n = 53) were selected from the Alzheimer's Disease Neuroimaging Initiative. MBI scores were derived from Neuropsychiatric Inventory items. Plasma Aβ42/Aβ40 ratios were assayed using mass spectrometry. Linear regressions were fitted to assess the association between MBI total score as well as MBI domain scores with plasma Aβ42/Aβ40.

RESULTS:

Lower plasma Aβ42/Aβ40 was associated with higher MBI total score (p = 0.04) and greater affective dysregulation (p = 0.04), but not with impaired drive/motivation (p = 0.095) or impulse dyscontrol (p = 0.29) MBI domains.

CONCLUSION:

In persons with normal cognition or mild cognitive impairment, MBI was associated with low plasma Aβ42/Aβ40. Incorporating MBI into case detection may help capture preclinical and prodromal Alzheimer's disease.

• Authors: Ruxin Miao, Hung-Yu Chen, Sascha Gill, James Naude, Eric E Smith, Zahinoor Ismail, Alzheimer’s Disease Neuroimaging Initiative
• Journal: Journal of geriatric psychiatry and neurology (J Geriatr Psychiatry Neurol) Vol. 35 Issue 3 Pg. 434-441 (05 2022) ISSN: 0891-9887 [Print] United States
• PMID: 34036829 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Amyloid beta-Peptides
• Biomarkers

Topics

• Aged
• Alzheimer Disease (complications, diagnostic imaging)
• Amyloid beta-Peptides
• Biomarkers
• Cognitive Dysfunction (complications, diagnostic imaging)
• Humans
• Neurodegenerative Diseases (complications)
• Neuropsychological Tests